Europe Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Europe Breast Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Europe Breast Cancer Screening Market will reach US$ 433.45 Million in 2028, according to Renub Research. Breast cancer is the leading form of cancer affecting women in Europe, with approximately 400,000 new cases annually and resulting in 100,000 fatalities. This type of cancer originates from malignant tumors that develop in breast cells. In rarer cases, breast cancer can also begin in the stromal tissues, encompassing the fatty and fibrous connective tissues of the breast. In 2020, breast cancer constituted 13.3% of all newly diagnosed cancer cases in the EU-27 countries, making it the most prevalent cancer type. Moreover, it accounted for 28.7% of all new cancer cases detected in women.

The growing awareness regarding the significance of breast cancer screening among women in Europe has contributed to an increased demand for screening services. This heightened awareness is the result of various initiatives including campaigns, educational programs, and advocacy groups that aim to encourage women to undergo screening. The aging population has also played a role in driving the demand for breast cancer screening, as the likelihood of breast cancer diagnosis is higher in older women.

To address this, European governments have implemented screening programs and policies to enhance access to breast cancer screening, particularly for underserved populations. Advancements in technology have led to the development of more precise and minimally invasive screening methods, such as digital mammography, breast ultrasound, and magnetic resonance imaging (MRI), which have significantly improved the detection of breast cancer.

The Europe Breast Cancer Screening Market is expected to experience a growth rate of approximately 3.19% from 2022 to 2028

In several European countries, comprehensive strategies involving Patient Support Programs and awareness campaigns have been implemented to promote early detection and treatment of breast cancer. Notably, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumabderuxtecan) has received approval in the European Union (EU) as a standalone therapy for adult patients with unrespectable or metastatic HER2-positive breast cancer, who have previously undergone one or more anti-HER2-based treatment regimens.

Enhertu is an innovative antibody-drug conjugate (ADC) that specifically targets HER2 and is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The European market has experienced revenue growth due to the approval of novel treatment approaches and significant investments in Research and Development by key industry players. In 2022, the Europe Breast Cancer Screening Market was valued at approximately US$ 359.1 Million, reflecting the substantial size of the industry within the region.

Germany commitment to improving breast cancer outcomes continues to drive its success in this vital healthcare sector

By Country, Europe Breast Cancer Screening Market is segmented into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. Germany holds the largest market share in the Breast Cancer Screening Market. The country's prominence can be attributed to several factors such as its robust healthcare infrastructure, well-established screening programs, and a proactive approach towards breast cancer awareness and early detection. Germany's emphasis on regular screening, coupled with advancements in technology and access to quality healthcare services, has contributed to its leading position in the market. Ongoing research and development activities, collaborations between academic institutions and industry players, and government initiatives further support Germany's dominance in the Breast Cancer Screening Market.

Spain innovative healthcare services drive rapid expansion, contributing significantly to enhancing breast cancer diagnosis and improving outcomes with a focus on quality

By Mammography Screening, Europe Breast Cancer Screening Market is classified into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. Spain is emerging as the fastest-growing market in the Breast Cancer Mammography Screening industry. The country's remarkable growth can be attributed to several factors. Spain has made substantial investments in advanced mammography technologies, ensuring accurate and early detection of breast cancer. The Spanish healthcare system has implemented comprehensive screening programs and initiatives, leading to increased awareness and participation among women.

Moreover, Spain's commitment to research and development, along with collaborations between healthcare institutions and industry leaders, has propelled the growth of the Breast Cancer Mammography Screening industry. With a focus on innovation and quality healthcare services, Spain is set to maintain its rapid expansion and make significant contributions to improving breast cancer diagnosis and outcomes.

United Kingdom is emerging as a rapidly growing market in the Breast Cancer MRI Screening industry in upcoming years

MRI Screening, Europe Breast Cancer Screening Market is divided into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. The United Kingdom (UK) is emerging as a rapidly growing market in the Breast Cancer MRI Screening industry. The country's significant progress can be attributed to several key factors. The UK has made substantial investments in state-of-the-art MRI technology, enabling precise and detailed imaging for breast cancer diagnosis.

Moreover, the UK's comprehensive healthcare system, combined with its strong emphasis on early detection and screening programs, has increased awareness and participation among women. The government's proactive approach, along with collaborations between healthcare institutions and industry leaders, has further fueled the growth of the Breast Cancer MRI Screening industry in the UK. With a focus on continual advancements and quality patient care, the UK is poised to continue its rapid expansion and make noteworthy contributions to improving breast cancer diagnosis and treatment outcomes.

Germany is playing a pivotal role in improving breast cancer diagnosis and patient outcomes through its expanding ultrasound screening market
Ultrasound Screening, Europe Breast Cancer Screening Market is sub-segmented into United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands. Germany ultrasound screening market in the Breast Cancer industry is experiencing notable growth. The Germany advancements in ultrasound technology, coupled with its robust healthcare system, have contributed to this positive trend. Germany emphasis on early detection and comprehensive screening programs has led to increased adoption of ultrasound as a reliable diagnostic tool for breast cancer. The country well-established infrastructure, including advanced imaging facilities and trained healthcare professionals, has further supported the growth of the ultrasound screening market. Germany commitment to research and development, along with collaborations between academia and industry, has facilitated continuous innovation in ultrasound technologies.

Key Player

In the Europe Breast Cancer Screening Market, prominent players such as AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc hold significant positions. These companies play a crucial role in driving advancements, innovation, and providing effective solutions for breast cancer screening across the region. Their significant presence reflects their commitment to improving breast cancer detection and contributing to better patient outcomes.

Renub Research report titled “Europe Breast Cancer Screening Market by type (Mammography Screening, MRI Screening, and Ultrasound Screening) by Country (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway and Netherlands) by Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, and GlaxoSmithKline plc)” provides a complete analysis of Europe Breast Cancer Screening Industry.

Types – Market has been covered from 3 viewpoints

1. Mammography Screening
2. MRI Screening
3. Ultrasound Screening

Countries – 8 European Country Breast Cancer Screening Market has been Covered

1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Switzerland
7. Norway
8. Netherlands

Company Insights:

• Overview
• Recent Development
• Sales Analysis

Companies Covered in the Report:

1. AstraZeneca
2. Novartis
3. Sanofi
4. Pfizer
5. Bayer AG
6. GlaxoSmithKline plc